New applications of disease genetics and pharmacogenetics to drug development

Allen D. Roses, Ann M. Saunders, Michael W. Lutz, Nanyin Zhang, Ahmad R. Hariri, Karen E. Asin, Donna G. Crenshaw, Kumar Budur, Daniel K. Burns, Stephen K. Brannan

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.

Original languageEnglish (US)
Pages (from-to)81-89
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

pioglitazone
Inborn Genetic Diseases
Pharmacogenetics
Oxygen Consumption
Rodentia
Genotype
Placebos
Clinical Trials
Brain
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Roses, A. D., Saunders, A. M., Lutz, M. W., Zhang, N., Hariri, A. R., Asin, K. E., ... Brannan, S. K. (2014). New applications of disease genetics and pharmacogenetics to drug development. Current Opinion in Pharmacology, 14(1), 81-89. https://doi.org/10.1016/j.coph.2013.12.002
Roses, Allen D. ; Saunders, Ann M. ; Lutz, Michael W. ; Zhang, Nanyin ; Hariri, Ahmad R. ; Asin, Karen E. ; Crenshaw, Donna G. ; Budur, Kumar ; Burns, Daniel K. ; Brannan, Stephen K. / New applications of disease genetics and pharmacogenetics to drug development. In: Current Opinion in Pharmacology. 2014 ; Vol. 14, No. 1. pp. 81-89.
@article{88c2c19c5d4b4f2aae1e2b09f8be3148,
title = "New applications of disease genetics and pharmacogenetics to drug development",
abstract = "TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.",
author = "Roses, {Allen D.} and Saunders, {Ann M.} and Lutz, {Michael W.} and Nanyin Zhang and Hariri, {Ahmad R.} and Asin, {Karen E.} and Crenshaw, {Donna G.} and Kumar Budur and Burns, {Daniel K.} and Brannan, {Stephen K.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.coph.2013.12.002",
language = "English (US)",
volume = "14",
pages = "81--89",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "1",

}

Roses, AD, Saunders, AM, Lutz, MW, Zhang, N, Hariri, AR, Asin, KE, Crenshaw, DG, Budur, K, Burns, DK & Brannan, SK 2014, 'New applications of disease genetics and pharmacogenetics to drug development', Current Opinion in Pharmacology, vol. 14, no. 1, pp. 81-89. https://doi.org/10.1016/j.coph.2013.12.002

New applications of disease genetics and pharmacogenetics to drug development. / Roses, Allen D.; Saunders, Ann M.; Lutz, Michael W.; Zhang, Nanyin; Hariri, Ahmad R.; Asin, Karen E.; Crenshaw, Donna G.; Budur, Kumar; Burns, Daniel K.; Brannan, Stephen K.

In: Current Opinion in Pharmacology, Vol. 14, No. 1, 01.02.2014, p. 81-89.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New applications of disease genetics and pharmacogenetics to drug development

AU - Roses, Allen D.

AU - Saunders, Ann M.

AU - Lutz, Michael W.

AU - Zhang, Nanyin

AU - Hariri, Ahmad R.

AU - Asin, Karen E.

AU - Crenshaw, Donna G.

AU - Budur, Kumar

AU - Burns, Daniel K.

AU - Brannan, Stephen K.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.

AB - TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=84891789152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891789152&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2013.12.002

DO - 10.1016/j.coph.2013.12.002

M3 - Review article

C2 - 24565016

AN - SCOPUS:84891789152

VL - 14

SP - 81

EP - 89

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -